Zacks Investment Research
Neutral
6/23 10:46 PM
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% change from its previous close.
The Motley Fool
Positive
6/22 6:53 PM
3 Reasons to Buy Bristol Myers Squibb Stock
Bristol Myers Squibb has a big revenue gap to fill, but it seems up to the challenge. Its robust dividend yield will pay investors handsomely to wait things out.
Business Wire
Neutral
6/18 10:59 AM
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026.
Business Wire
Neutral
6/17 8:16 PM
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Benzinga
Positive
6/17 4:43 PM
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is up on Wednesday as the company reported promising clinical observations regarding its ELI-002 7P treatment.
Forbes
Neutral
6/17 4:30 PM
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Zacks Investment Research
Positive
6/17 2:02 PM
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research
Positive
6/16 7:21 PM
Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio?
Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.
The Motley Fool
Positive
6/16 10:15 AM
3 Dividend Stocks to Hold for the Long Haul
These three healthcare leaders are slowly overcoming recent obstacles. They have strong dividend track records and the means to maintain healthy dividend growth.
24/7 Wall Street
Positive
6/15 2:50 PM
A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb
With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds.
52W Range
$42.52 - $62.89
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
